COIOSDeep risk insights through multi-disciplinary research across the globe
cars parked on side of the road during daytime
Item refines Peer-reviewed Added

GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes with obesity

In Clalit's medical records, liraglutide and dulaglutide matched SGLT-2 inhibitors on weight loss but lowered HbA1c more.

This study used Clalit's medical records to compare GLP-1 receptor agonists with SGLT-2 inhibitors in type 2 diabetes and obesity. Target trials were emulated for 4,296 liraglutide, 11,159 dulaglutide and 5,041 semaglutide initiators, with inverse-probability weighting. Five-year weight loss with liraglutide and dulaglutide, at 6.4-7.3 kg, was similar to SGLT-2 inhibitors. At 18 months, semaglutide gave 2.6 kg (95% CI 1.2-4.0) more weight loss than SGLT-2 inhibitors. At 18 months HbA1c fell 0.4%, 0.7% and 0.6% more with liraglutide, dulaglutide and semaglutide, an advantage maintained throughout follow-up. The data are observational, and semaglutide follow-up ran only three years against five for the others.

Why it is interesting: Long-term head-to-head randomised trials of these drug classes are lacking. These analyses extend short-term trial evidence to five years for liraglutide and dulaglutide.

Source
Diabetes, Obesity and Metabolism, 9 November 2026
Paper
Effectiveness of GLP-1 RAs and SGLT-2is for Weight Loss and Glycaemic Control: An Observational Emulation of a Target Trial
Authors
Silverbeck J, Roitman E, Vodonos Zilberg A, Balicer R, Dagan N, Hernán MA
DOI
10.1111/dom.71515
Type
Peer-reviewed article
Design
Target trial emulation in Clalit electronic medical records; 4296 liraglutide, 11159 dulaglutide, 5041 semaglutide initiators vs SGLT-2i, inverse-probability weighting, follow-up to 5 years (3 for semaglutide)
Verdict
Refines prior evidence
Driver
Obesity, diabetes and GLP-1

Other drivers in Health today